New analysis helps guide use of erlotinib in advanced non-small cell lung cancerApril 18, 2012
Lugano-CH/Aurora-US-CO/Geneva-CH, 18 April 2012 -- Patients with advanced non-small cell lung cancer should only receive treatment with the drug erlotinib before receiving standard chemotherapy if their tumor is known to harbor EGFR mutations, researchers report at the 3rd European Lung Cancer Conference in Geneva, Switzerland.
The results of biomarker analyses of a recently reported clinical trial confirm that patients with unknown or negative mutation status should be treated with the standard chemotherapy first, they say.
The TORCH trial was a randomized phase III trial conducted in Italy and Canada, which compared the efficacy of treatment with erlotinib, followed at progression of disease by cisplatin and gemcitabine, against the standard reverse sequence. Erlotinib is a drug that specifically targets the epidermal growth factor receptor (EGFR) tyrosine kinase.
The primary endpoint of the original TORCH study was overall survival and 900 patients were planned, however the study was stopped early as the first interim analysis showed that the erlotinib-first regimen was inferior to the standard approach.
In the new study, Dr Ming Tsao and colleagues conducted an exploratory analysis on the TORCH patient tumor samples that were available for analysis, looking for molecular biomarkers known to be potential predictors of benefit from EGFR inhibitors.
"Our results show a significant interaction in progression-free survival favoring treatment with erlotinib first in EGFR-mutated patients, and favouring first treatment with chemotherapy in EGFR wild type [non-mutated] patients," said Dr Tsao, from the Princess Margaret Hospital.
"However there was no significant interaction between treatment efficacy and overall survival. This shows that using erlotinib to treat patients with a mutated tumor is always effective, both in first and in second line; of course, it is much more convenient for these patients to receive it as first line, as shown also in other trials," Dr Tsao said.
Patients with EGFR mutations benefit from the erlotinib-first regimen because their tumors are very sensitive to the anti-tumor activity of the drug, he explained.
"The take-home message from this study is that in advanced non-small cell lung cancer patients, treatment with erlotinib first should only be applied to patients whose tumor is known to harbor EGFR mutation," said Dr Tsao. "Patients with unknown or negative mutation status should be treated with the standard chemotherapy first."
Commenting on the study which he was not involved in, Dr Tetsuya Mitsudomi from Aichi Cancer Center Hospital in Nagoya, Japan, member of the IASLC Board of Directors, said: "Many previous trials, for instance IPASS, NEJ002, WJTOG3405, OPTIMAL, EUROTAC, have already shown that EGFR mutation is the most reliable predictive marker for EGFR-TKI treatment. The current paper was able to confirm the importance of EGFR mutation testing when considering the use of erlotinib, especially in consideration of the far shorter progression-free survival obtained with erlotinib when the mutation was absent. Consequently, although it was thought that erlotinib is active even in lung cancer patients without EGFR mutation if compared with gefitinib, this study suggests that erlotinib should be avoided when treating patients without EGFR mutation, at least in the first-line setting."
This biomarker analysis was preplanned but actually only 36% of the samples could be anlayzed for EGFR mutation. This relatively low tissue accrual rate is precedented by many clinical trials in which the mutation analysis was performed retrospectively. "Therefore, we also have to consider prospective determination of oncogene mutation when we want to raise this rate such as in NEJ, WJTOG, OPTIMAL and EUROTAC," Dr Mitsudomi added.
"In summary, the TORCH-BIO study adds imprortant evidence to the research field of EGFR-TKI in lung cancer and emphazizes the importance of biomarker study for improvement of clinical outcome."
European Society for Medical Oncology
Related Lung Cancer Articles:
Lung cancer has been the leading cause of cancer-related deaths in 2015 in United States.
The first year of free lung cancer screening in the Augusta, Ga., area found more than double the rate seen in a previous large, national study as well as a Massachusetts-based screening for this No.
An epidemiological study published in Frontiers in Oncology suggests that a diet high in carotenoids and vitamin C may protect against lung cancer.
Could lung cancer be hiding in kidney cancer patients? Researchers with the Harold C.
Cancer Research UK, Cancer Research Technology (CRT), the charity's commercial arm, and HitGen Ltd, a privately held biotech company focused on early drug discovery, announced today that they have entered into a licence agreement to develop a novel class of drugs against lung cancer.
East Asian female breast cancer patients receiving radiotherapy have a higher risk of developing second primary lung cancer.
New research from scientists at Huntsman Cancer Institute (HCI) at the University of Utah uncovered distinct types of tumors within small cell lung cancer that look and act differently from one another.
Researchers from Kumamoto University, Japan have found that postmenopausal women with multicentric adenocarcinoma of the lung have a higher concentration of estrogen in non-cancerous areas of the peripheral lung than similar women diagnosed with single tumor lung cancer.
Researchers have found that treating patients who have early stage non-small cell lung cancer with a type of radiotherapy called stereotactic body radiation therapy is associated with a small but increased risk of death from causes other than cancer.
Pericardial window operation, a procedure, where abnormal quantity of malignant fluid, surrounding the heart, is drained into the neighbouring chest cavity, is commonly applied to patients diagnosed with cancer.
Related Lung Cancer Reading:
How to Survive Lung Cancer - A Practical 12-Step Plan
by Michael Lloyd (Author)
Written by a lung cancer survivor who understands what it takes to beat the odds, this book offers unparalleled hope and direction for anyone facing this illness. It is filled with specific exercises and techniques to promote healing and reverse side effects by taking a pro-active approach in helping to restore your mind, body and spirit to an optimum state of health. Endorsed by a Lung Cancer Specialist and Associate Professor at Harvard Medical School, this book combines what the doctors tell you with critical information they don't tell you. Visit www.SurviveLungCancer.com for chapter... View Details
The ABCs of Lung Cancer: for Patients and Advocates
by Dusty Joy Donaldson (Author), Kimberly D. Lester (Author), Kimberly D. Lester (Illustrator)
Learn valuable lessons from a longtime lung cancer survivor’s own journey The ABCs of Lung Cancer is a practical, easy-to-read guide for lung cancer patients and the people who care for and about them. Written by an 11-year lung cancer survivor and her daughter, the authors provide useful tips for dealing with and preventing lung cancer, some anecdotes about their own experiences, and, most of all, hope. Structured logically from A–Z, The ABCs of Lung Cancer gives frank advice that is easy to digest, despite the serious topic. Each segment offers insight garnered from the authors’... View Details
Bonnie J. Addario Navigating Lung Cancer 360 Degrees of Hope
by Bonnie J. Addario (Author), MD, PhD, Shane P. Dormady (Author), RN, MSN, CPHQ, Eileen Johnson (Author), RN, MBA, Alicia Sable-Hunt (Author), Danielle Hicks (Editor), MD, Paul Hesketh (Editor), MD, Robert Sinha (Editor), MD, PhD, D. Ross Camidge (Editor), MD, Elizabeth A. David (Editor), MD, Lisa Boohar (Editor), MD, David R. Gandara (Editor), PhD, Guneet Walia (Editor), Inc., Sheila Von Driska?White Space (Editor)
Navigating Lung Cancer 360 Degrees of Hope is the most comprehensive guidebook for surviving lung cancer. Inside each latest edition you will get the most up-to-date navigation tools on the diagnosis process, lung cancer staging, treatment options, clinical trials, living with lung cancer, financing your care, hope for surviving lung cancer, and more. Written by survivor Bonnie J. Addario and the leading experts in lung cancer with one goal: to turn lung cancer into a manageable and survival disease. View Details
100 Questions & Answers About Lung Cancer (100 Questions and Answers)
by Joan H. Schiller (Author), Amy Cipau (Author)
No one with lung cancer needs to be alone in their fight against this disease. 100 Questions & Answers About Lung Cancer, Third Edition, guides patients and their families through diagnosis, treatment and survivorship. Providing both the doctor's and patient's point of view, this book is a complete guide to understanding treatment options, post-treatment quality of life, sources of support, and much more. Through 100 Questions & Answers About Lung Cancer, Third Edition, expert authors use their experiences with patients to provide support and hope to the tens of... View Details
Lung Cancer: From Diagnosis to Treatment
by Walter Scott MD (Author)
According to the American Cancer Society, nearly 220,000 Americans are diagnosed with lung cancer annually. It accounts for nearly 15 percent of all newly diagnosed cancers. If you've been diagnosed, you probably have many questions about the nature of the disease and your treatment options.Walter J. Scott, M.D., has treated thousands of lung cancer patients who have navigated this overwhelming maze of medical tests and procedures. In Lung Cancer: From Diagnosis to Treatment, Dr. Scott helps you understand the process—from getting a diagnosis to going through treatment. He explains... View Details
You Can Beat Lung Cancer: Using Alternative/Integrative Interventions
by Carl O. Helvie (Author)
Can you overcome lung cancer without harsh chemicals, surgery and debilitation? Are alternative interventions effective? Why do conventional physicians not use them? Can you prevent cancer recurrences and live into old age without chronic diseases and prescribed medications? This book answers these and other questions.
This is one of the most comprehensive books available on alternative treatments for lung cancer. It explains the treatments used successfully by a health professional/cancer survivor of 36 years and by some of the leading medical and health practitioners currently in the... View Details
Lung Cancer: A Multidisciplinary Approach
by Alison Leary (Editor)
Lung Cancer: A Multidisciplinary Approach provides clinicians with a comprehensive text that can be used when caring for patients with lung cancer throughout the entire patient journey. This edited collection explores the aetiology of lung cancer; mesothelioma; the range of available treatments, including chemotherapy and radiotherapy; surgical care; supportive and end-of-life care; quality-of-life issues; and the role of the nurse within the multidisciplinary team.A comprehensive, evidence-based guide to lung cancer Illustrative case studies used throughout Contributions from... View Details
Principles and Practice of Lung Cancer: The Official Reference Text of the International Association for the Study of Lung Cancer (IASLC)
by Harvey I. Pass MD (Editor), David P. Carbone MD PhD (Editor), David H. Johnson MD (Editor), John D. Minna MD (Editor), Giorgio V. Scagliotti MD (Editor), Andrew T. Turrisi III MD (Editor)
Thoroughly revised and updated, this Fourth Edition is the most comprehensive, current reference on lung cancer, with contributions from the world's foremost surgeons, radiation oncologists, medical oncologists, pulmonologists, and basic scientists. Coverage includes complete information on combined modality treatments for small cell and non-small cell lung cancer and on complications of treatment and management of metastases. Emphasis is also given to early detection, screening, prevention, and new imaging techniques.
This edition has expanded thoracic oncology chapters including... View Details
Living with Lung Cancer--My Journey
by Thomas E. Cappiello (Author)
On October 5 2007, Thomas Cappiello was diagnosed with inoperable Stage IIIA locally-advanced adenocarcinoma (Non-Small Cell Lung Cancer), an incurable disease. This book is the inspirational story of how he beat the odds and survived and thrived in the face of this devastating illness. This book is for patients and caregivers who want to know what life is like after getting a cancer diagnosis. The story is about overcoming the emotional turmoil and devastation of a cancer diagnosis, dealing with the disease, and making choices. Most of all, it's about living a full life each day. Cancer... View Details
Anticancer: A New Way of Life
by David Servan-Schreiber MD PhD (Author)
The revolutionary, New York Times bestselling guide to the powerful lifestyle changes that fight and prevent cancer—an integrative approach based on the latest scientific research
“A common-sense blueprint for healthy living.” —Chicago Tribune
“Resonating with cancer support communities and recommended nationwide.” —Los Angeles Times
“Life affirming . . . filled with practical advice.” —The Seattle Times
David Servan-Schreiber was a rising... View Details